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INTRODUCTION
Warfarin, the most commonly used oral anticoagulant in the 
world, is indicated for the prevention and treatment of throm-
boembolic events in patients with deep vein thrombosis, pul-
monary embolism, atrial fibrillation and prosthetic heart 
valves. It is administered as a racemic mixture of S-warfarin 
and R-warfarin. S-warfarin is the more active isomer and has 
a greater therapeutic effect. These enantiomers are extensively 
metabolized by various cytochrome P450 enzymes. R-warfa-
rin is mainly metabolized by cytochrome P450 1A2 (CYP1A2), 
CYP2C19, and CYP3A4, while S-warfarin is predominantly 
metabolized by CYP2C9.1 Both enantiomers affect the coagu-
lation cascade by inhibiting the activity of vitamin K epoxide 
reductase complex 1 (VKORC1), thus interfering with the acti-
vation of clotting factors II, VII, IX, and X.2 However, despite its 
considerable benefit, warfarin is less frequently prescribed 
than it should be,3 because of it’s relatively high adverse event 
rate and the difficulty in managing the therapy.4 Common ad-
verse drug events (ADEs) arising from warfarin treatment in-
clude major and minor bleeding and hemorrhagic stroke.5 
ADEs are also frequently due to insufficient therapy: ischemic 
stroke and venous thromboembolism.6 Warfarin, which has 
narrow therapeutic index, shows not only large inter-individ-
ual variations in dose response but also intra-individual varia-
tion. Because patients’ clinical characteristics such as age, gen-
der, body weight, concurrent medications, diet, co-morbidities 
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and patient compliance level have shown to have large influ-
ence on warfarin dosing,7 frequent monitoring of its effect, as 
measured by the international normalized ratio (INR), is war-
ranted. 
CYP2C9 and VKORC1 have been identified as important ge-
netic determinants of warfarin dosing. The most common CY-
P2C9 genotype among all ethnic is CYP2C9*1 and found in 
about 80% of Caucasians8 and 93% of Korean.9 Lindh, et al.10 
demonstrated that carriers of CYP2C9*2 and CYP2C9*3 alleles 
require less warfarin dose than carriers of wild type CYP2C9*1 
genotype. Difference in allelic frequencies are also observed 
with the most common single nucleotide polymorphisms (SNPs) 
in the VKORC1 gene, 1173C>T (rs9934438). Approximately, 35% 
of caucasians carry CC genotype, while only about 15% carry 
the TT genotype. However, most of the Korean showed TT gen-
otype, but less than 1% carry CC genotype.11 Carriers of 1173CC 
and 1173CT genotype need 44% and 97%, respectively, more 
warfarin dose than carriers of 1173TT genotype.12 The clinical 
algorithms for determining warfarin dose containing clinical 
characteristics and pharmacogenetics information of the pa-
tients have been developed for more proper warfarin dose 
prediction. These algorithms are not intended to replace INR 
monitoring, but to increase the accuracy and reduce trial and 
error approach in warfarin dosing. According to International 
Warfarin Pharmacogenetics Consortium (IWPC) study,13 the 
algorithms using clinical and genetic information increase the 
accuracy in dose prediction than a fixed-dose approach or al-
gorithms derived from clinical information. In addition, they 
are useful, especially in the patients who may be administered 
more or less than appropriate dose.13 
Personalized dosing and INR monitoring are required, be-
cause response to warfarin is different depending on the indi-
cation and the state of the disease. The studies on warfarin dose 
assessment so far was mainly targeted at valvular heart dis-
ease, deep vein thrombosis and atrial fibrillation.13-21 On the 
other hand, warfarin is widely used to prevent the recurrence 
of stroke, which occupied the second place in the current 
causes of death in Korea, nevertheless, there are only a few 
studies to compare the predictive power of the dosing control 
based on a pharmacogenetics. This study reviewed prescribed 
dose and actual INR response in patients with stroke and 
compared the accuracy of 10 warfarin dose prediction algo-
rithms based on the pharmacogenetics. In addition, warfarin 
dosing algorithm for Korean patients with stroke was devel-
oped to increase the quality of care for stroke patients.
MATERIALS AND METHODS
Study subjects
A total of 129 patients undergoing warfarin treatment for pre-
vention and treatment of stroke and requesting genotyping of 
CYP2C9 and VKORC1 were recruited retrospectively at the 
neurology clinic at the Severance Hospital, Seoul, Korea. All 
study participants were enrolled between January 2009 and 
December 2014. Patients included were adults, whose warfa-
rin dose requirement had remained constant for at least 3 pre-
vious clinic visits over a minimum period of 3 months, and with 
an INR of the prothrombin time within the range of 1.5 to 3.0.22 
Twenty-eight patients were excluded from the study according 
to enrolment criteria. This study was approved by the Institu-
tional Review Board of the Yonsei University Severance Hos-
pital, Seoul, Korea. Written informed consent was obtained 
from the patients. 
Demographic and clinical data collection
Data were collected from patients’ medical records. These data 
included demographic characteristics, comorbidities, the sta-
ble therapeutic dose of warfarin, the INR achieved with a stable 
warfarin dose, the use of concomitant medications, and the 
genotype of CYP2C9 and VKORC1. The interacting drugs, 
which is defined based on previously published literature, were 
also reviewed.23,24
Genotyping
Genomic DNA was extracted from EDTA whole blood samples 
with QIAamp DNA Extraction Kit (Qiagen, Hilden, Germany). 
For determination of the CYP2C9 genotype, the CYP2C9*3 
(1075A>C; rs1057910) SNP is selected. For VKORC1 geno-
types, the VKORC1 1173C>T (rs 9934438) SNP is determined. 
PCR and direct sequencing were performed using primers 
designed in Primer3 software (http://bioinfo.ut.ee/prim-
er3-0.4.0/). Purified PCR products were obtained using a QIA-
quick Gel Extraction Kit (Qiagen, Düsseldorf, Germany) and 
were sequenced using a Big Dye Terminator Cycle Sequenc-
ing Ready Reaction Kit (Applied Biosystems, Foster City, CA, 
USA). Sequences were analyzed using an ABI 3500dx system 
(Applied Biosystems). To detect any sequence variation, the se-
quences were compared to the reference sequences using Se-
quencher software (Gene Codes, Ann Arbor, MI, USA). 
Dosing algorithms
A literature search from Pubmed database was performed, with 
the search terms warfarin, algorithm, polymorphism, CYP2C9 
and VKORC1, to select warfarin dosing algorithms. Algorithms 
were included based on the following criteria; 1) equations to 
predict maintenance warfarin dose, 2) only two SNPs consist-
ing of VKORC1 1173G>T (or VKORC1 -1639G>A and 2255C>T) 
and CYP2C9*2 and/or *3, 3) published in English, 4) equations 
containing available clinical parameters, 5) algorithms were 
selected, depending on a historical aspect (e.g., the first warfa-
rin dosing model), the size or ethnicity of the study population. 
Studies that enrolled adult patients with atrial fibrillation, ve-
nous thromboembolic diseases, recent orthopedic surgery, 
valvular disease, and stroke were also included. Wherever gen-
otype is missing, we imputed its value based on other VKORC1 
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SNPs, because VKORC1 1173 genotype is suggested to be in 
complete linkage disequilibrium with VKORC1 -1639 and 
2255.13,25
Nine algorithms were selected from the literature that met 
our inclusion criteria. These are referred to as Sconce, et al.,15 
Anderson, et al.,20 Gage, et al.,14 Wu, et al.,21 IWPC,13 Wadelius, et 
al.,17 Huang, et al.,19 Ohno, et al.,16 and Cho, et al.18 throughout 
this manuscript. 
Data analysis
Warfarin doses between the different genotypes were com-
pared using the Mann Whitney U-test. Predictive accuracy was 
assessed by comparing the dose predicted by the nine algo-
rithms to actual dose which the patient was taking. Predicted 
dose was calculated using published equations, except Gage’s 
calculated by input on the website http://www.warfarindos-
ing.org. A best fit trendline and correlation coefficient were 
determined by linear regression. In addition, the mean of per-
cent deviation of predicted doses from the actual dose was 
used to evaluate the predictive accuracy of each algorithms. 
In addition, we compared the performance of the algorithms 
using percentage of predicted dose falling within ±20% of 
clinically observed doses26 and dividing the patients into low-
dose group (≤3 mg/day), intermediate-dose group (3–7 mg/
day), and high-dose group (≥7 mg/day).13 Stepwise multiple 
regression analysis was performed to develop new warfarin 
dosing algorithm, and the results of univariate analysis were 
used to choose predictors for multivariate analysis. All statisti-
cal tests were performed with a p value<0.05 significance. All 
analyses were performed using the Statistical Package for So-
cial Science (SPSS 18.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Characteristics of the study groups
The characteristics of all 101 patients are listed in Table 1. A to-
tal of 101 patients with a mean age 64 years (SD, ±13.4) ranging 
from 27 to 88 years, included 64 males (63%). The mean body 
weight was 64.6 kg (SD, ±10.5), and the mean body surface area 
was 1.7 (SD, ±0.2). The mean stable warfarin dose was 3.74 mg/
day (SD, ±1.43). Concurrent diseases associated with these 
patients included atrial fibrillation (63 patients, 62%), hyper-
tension (52 patients, 52%), diabetes mellitus (27 patients, 27%), 
heart disease including coronary arterial occlusive disease (14 
patients, 14%), heart failure (7 patients, 7%), and cardiac valvu-
lar disease (9 patients, 9%). Other sources of cardioemboilism 
including patent foramen ovale and left atrial thrombus were 
identified, in addition to heart problem that is shown in the Ta-
ble 1. A total of 44 (44%) patients were receiving comedication 
that could affect the anticoagulation effect of warfarin, includ-
ing amiodarone, aspirin, antiplatelet drugs, statins, thyroid hor-
mone, and verapamil. 
Effects of genotype on stable dose of warfarin
Table 2 shows daily warfarin dose of different genotypes. For 
CYP2C9, 97 patients (96%) were identified to be homozygous 
for CYP2C9*1, and 4 patients (4%) were heterozygous for CY-
P2C9*3. No patients with CYP2C9*2 allele were identified. The 
frequency of the VKORC1 1173TT genotype was 82% and that 
of 1173CT genotype was 17%, and only 1 patient was homozy-
gous for the variant C allele. In our study, no patients with ho-
mozygous CYP2C9*3/*3 were identified, and the CYP2C9 and 
VKORC SNPs for Korean were in Hardy-Weinberg equilibri-
um. The stable warfarin doses for patients with VKORC1 TT 
type (3.6±1.2 mg/day) were significantly lower than those for 
patients with any other VKORC1 genotype (p<0.05). However, 
Table 1. Characteristics of the Study Population 
Variables n=101
Men (%) 64/37 (63/37)
Mean age (SD) (range), yr 63.6 (13.4) (27–88)
Body weight (SD) (range), kg 64.6 (10.5) (44–90)
Mean BSA (SD) (range), m2 1.7 (0.2) (1.3–2.1)
Smoking patients (%) 31/101 (31)
Concurrent disease (%)
Atrial fibrillation 63/101 (62)
Cancer 1/101 (1)
Cardiac valvular disease 9/101 (9)
Cervicocephalic artery dissection 5/101 (5)
CHF/cardiomyopathy 7/101 (7)
CAOD 14/101 (14)







Antiplatelet drug 14/101 (14)
Statins 70/101 (69)
Thyroid hormone 1/101 (1)
Verapamil 24/101 (24)
BSA, body surface area; CHF, congestive heart failure; CAOD, coronary arte-
rial occlusive disease.
Table 2. Effects of VKORC1 1173C>T and CYP2C9 Genotypes on Warfa-
rin Stable Dose
Genotype n Warfarin dose (mg/day) p value
VKORC1 1173 <0.05
CC 1 6.0
CT 17 4.6±1.9 
TT 83 3.6±1.2 
CYP2C9*3 0.080
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the difference in the stable warfarin dose between patients with 
homozygous for CYP2C9*1 (3.8±1.4 mg/day) and heterozy-
gous for CYP2C9*3 (2.6±0.5 mg/day) was not significant. 
Establishing of dosing algorithm
For multiple linear regression analysis, 4 variables, including 
age, bodyweight, CYP2C9*3 and VKORC1 1173 genotypes, were 
selected (R2=0.51) (Table 3). We established the warfarin dos-
ing formula with following equation: maintenance dose=exp 
[1.756-0.015 (age)+0.006 (body weight)-0.284 (CYP2C9 geno-
type)+0.407 (VKORC1 genotype)]. It was coded as 1 in the case 
of the presence of the CYP2C9 variant, or the presence of the 
VKORC1 1173C allele. 
Dosing algorithm comparison
A comparison of the ten algorithms for determining warfarin 
doses is shown in Table 4. Most algorithms that evaluated, in-
cluding the dosing algorithm derived from this study, had a 
good correlation. However, the algorithms by Gage, et al.,14 Wu, 
et al.,21 and Huang, et al.19 showed poor correlation. Among 
these 7 algorithms, algorithms from this study, Sconce, et al.,15 
Anderson, et al.,20 and Ohno, et al.16 produce similar accuracy 
with mean deviation ranging from -10.0 to 4.3. These algo-
rithms were selected based on their correlation coefficient (r> 
0.6) and the mean deviation from the actual dose (mean devi-
ation about 10%) for further analysis. The algorithm from this 
study provided significantly better prediction fell within 20% 
of the actual dose (Table 5). Others performed similarly to pre-
dict ideal dose. Algorithms by Sconce, et al.15 and Ohno, et al.16 
tend to underestimate in about 40% of cases. In addition, the 
accuracy of this study and Anderson, et al.20 was better than 
others for patients who need intermediate-dose group (Table 
6). For patients who need less than 3 mg/day, algorithm by 
Ohno performed well. However, for patients who required 
more than 7 mg/day, all algorithms performed poorly, with un-
derestimation for all patients.
DISCUSSION
Warfarin, the first human anticoagulant, remains the most 
commonly prescribed oral anticoagulant in the world. Warfa-
rin exerts its effect by inhibiting the activity of VKORC1, thus 
interfering with the activation of vitamin K-dependent clotting 
factors II, VII, IX, and X.2 Warfarin is underutilized for stroke 
prevention. The Agency for Healthcare Policy and Research 
noted that physicians avoid to prescribe warfarin, because they 
are not familiar with techniques for administrating the drug 
safely and fear bleeding complication.3,4 Warfarin therapy is 
Table 3. Contribution of Individual Variables to the Algorithm
Variables R (R2adj) Slope (beta) Standard error p value
All 0.73 (0.51) 
Age 0.58 (0.33) -0.15 0.002 <0.001 
Body weight 0.01 (0) 0.006 0.003 0.017
CYP2C9 0.02 (0.01) -0.284 0.134 0.037
VKORC1 0.13 (0.17) 0.407 0.069 <0.001 
R2adj, R2 adjusted.
Table 4. Comparison of the Warfarin Dosing Algorithms
Algorithm Derivation sample (n) R R2 (R2adj) Mean deviation (%) Regression equation 
This study 101 0.73 0.53 (0.51) 3.3 y=0.406x+1.886 
Gage, et al.14 1015 0.57 0.33 (0.32) -7.1 y=0.453x+1.546 
Sconce, et al.15 297 0.62 0.38 (0.38) -9.9 y=0.394x+1.676 
Wu, et al.21 92 0.36 0.13 (0.12) 46.4 y=0.208x+4.105 
Anderson, et al.20 213 0.69 0.48 (0.47) 4.3 y=0.301x+2.427 
Ohno, et al.16 125 0.65 0.42 (0.41) -10.0 y=0.316x+1.913 
Huang, et al.19 266 0.49 0.24 (0.23) -16.9 y=0.237x+1.940 
Wadelius, et al.17 1496 0.63 0.40 (0.39) 50.8 y=0.360x+3.748 
IWPC13 4043 0.61 0.37 (0.37) -17.9 y=0.324x+1.634 
Cho, et al.18 130 0.64 0.41 (0.41) -49.7 y=0.094x+1.336 
R2adj, R2 adjusted.
Table 5. Percentage of Patients with an Ideal, Underestimated, or Over-








This study 53 22 26
Anderson, et al.20 50 20 31
Sconce, et al.15 46 40 15
Ohno, et al.16 46 42 13
*Predicted doses falling within ±20% of clinically observed doses.
Table 6. Sensitivity Analysis with Low-, Intermediate-, and High-Dose 
Patient Groups 
Algorithm 
Subgroups based on the warfarin dose 
≤3 mg/d 
(n=50) 




This study 48 63 0
Anderson, et al.20 40 63 0
Sconce, et al.15 52 42 0
Ohno, et al.16 62 31 0
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challenging, because warfarin has narrow therapeutic index. 
In addition, it shows not only large inter-individual variations 
in dose response but also intra-individual variation. Because 
patients’ clinical characteristics such as age, gender, body 
weight, concurrent medications, diet, co-morbidities and pa-
tient compliance level largely influence warfarin dosing,7 fre-
quent monitoring of its effect, as measured by the INR, is war-
ranted. 
CYP2C9 and VKORC1 have been identified as important 
genetic determinants of warfarin dosing. Two prospective stud-
ies20,27 on genotype-guided warfarin dosing predicted more 
accurately, resulting in reduction of dosing changes, minor 
bleeding complication, and time to reach therapeutic range. 
Although numerous warfarin dosing algorithms have been de-
veloped, their indications for warfarin usage were heteroge-
neous. Until now, there has been no consensus pharmacoge-
netic-guided algorithm. 
In the present study, we developed an algorithm to provide 
a practical warfarin dosing for Korean patients with stroke. The 
warfarin dosing algorithm was developed on a homogeneous 
population and single disease indication for stroke, since war-
farin have been underused for prevention of stroke and there 
are few studies on warfarin dosing algorithm focused on stroke 
patients. Because the distribution of warfarin dose is skewed, 
we created dosing algorithm for log transformation of doses, as 
evidenced by a mean percent deviation that was lower than 
that for both the raw doses square root of doses. Other variables 
including age and body weight showed normal distribution. 
We analyzed whether ten selected dosing algorithms, includ-
ing the algorithm derived in the present study, could accurately 
predict warfarin dose in the study population, and found that 
the present algorithm demonstrated good correlation with 
actual dose, with coefficient of determination (R2) of 0.51. Al-
gorithm in this study is consisted of five factors; age, body 
weight, and genotypes of CYP2C9 and VKORC1. While reduced 
incorporated factors are convenient for physicians to use, this 
algorithm performed better than Gage, et al.,14 Wu, et al.,21 and 
Huang, et al.19 The VKORC1 and CYP2C9 genotypes account-
ed for about 14% of the inter-individual variation of the mainte-
nance daily warfarin dose. Because allele frequencies of VKORC1 
and CYP2C9 are different depending on race, the R2 values of 
these genes differ among studies. 
Anderson, et al.,20 Ohno, et al.,16 and Sconce, et al.15 also 
showed good linear relationship with actual dose and pre-
dicted dose. However, the R2 indicated the linearity of the as-
sociation only, and the mean deviation from actual dose is a 
better measure of the algorithms’ performance. Although the 
above three algorithms showed a good correlation with the 
actual dose in our study population, a better prediction of dos-
age was achieved by our model.
The algorithm devised by Cho, et al.18 was the latest warfarin 
dosing algorithm for Korean patients with atrial fibrillation 
and the best model for prediction of daily maintenance dose. 
This algorithm showed a good relationship between the actu-
al dose and the predicted warfarin dose in our study popula-
tion as reported previously. However, this algorithm was the 
worst performing algorithm by means of the mean deviation. 
The mean age, the strongest predictor of warfarin dose, was 
slightly older in cohort of Cho, et al., although its significance 
is unclear. Because these two algorithms developed for two 
different single disease indication; atrial fibrillation and stroke, 
these patients may be differently influenced by environmental 
factors such as coadministered drugs and comorbidities. Atri-
al fibrillation was indeed the most common indication of war-
farin usage in this study. Likewise western countries,28 cervi-
cocephalic artery dissections were common causes of stroke 
in young patients under 45. Cho, et al.18 reported that statin 
influences the daily dose of warfarin. Simvastatin, fluvastatin, 
and lovastatin potentiate warfarin’s effect.24,29 In our study, 
most patients were taking statin such as atorvastatin, pitavas-
tatin, and rosuvastatin which do not affect the warfarin’s ef-
fect. There is no correlation between daily dose of warfarin and 
statin status regardless of types of statin.
The algorithm derived in the present this study was less pre-
dictable among patients who required high doses of warfarin 
(≥7 mg/day). As this study was a small retrospective analysis 
with only a few patients requiring high doses, the results might 
have been skewed because of the individual patients varia-
tions. About 3% of the patients could have complication due 
to underdose. Of the three outliers, two patients were VKORC1 
CT genotype. The other was TT type and he was taking antitu-
berculosis drug. Rimfampin decreases INR increase via in-
duction of hepatic metabolism of warfarin.24 Removal of these 
three data points did not improve the correlation coefficient for 
our algorithm (R2=0.51). However, the sample size was too 
small to make a conclusion on the efficacy of the dosing algo-
rithms in this population. 
In this study, we found 0 and 4% prevalence of CYP2C9*2 
and CYP2C9*3, respectively, which is consistent with the re-
port of Cho, et al. who also found no CYP2C9*2 and a 8.5% prev-
alence of *3. For VKORC1, we found 82%, 17%, and 1% preva-
lence of VKORC1 TT, CT, CC genotype, respectively, which 
compares with the report of Cho, et al. who found 75.4%, 23.1%, 
and 1.5%, respectively. 
Our study has several limitations. First, we did not have suf-
ficient data to include potentially important factors such as vi-
tamin K intake or compliance of administration even if we ed-
ucated the patients when starting warfarin. However, the 
percentage of variability in warfarin dosing in our study is simi-
lar to that in other compared models, therefore, the effect of 
these variables is probably small. Second, because we investi-
gated only one VKORC1 SNPs, requiring us to impute missing 
genotype for evaluating some models. Therefore, we substi-
tuted missing genotype based on linkage disequilibrium, which 
is generally reliable.25 Nevertheless, it may cause error that 
would lead to decrease of the accuracy of our model. Third, only 
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4% of the study population was younger than 40 years of age; 
therefore, additional models for stroke patients with younger 
age are needed, as age is important factor of prediction. 
In order to further improve dosing algorithms, additional 
study is necessary in efforts to find new genes and SNPs con-
tained with these genes that influence warfarin pharmacoki-
netics and pharmacodynamics. Although the incorporation of 
additional variables could improve predictive algorithm, the 
gains may be modest and probably do not justify the cost ef-
fectiveness and improvement of clinical outcome. In addition, 
studies on clinical utility of these pharmacogenetic-guided al-
gorithms should be performed. 
In conclusion, we developed warfarin dose prediction algo-
rithm for patients with stroke, and it explained 51% of the varia-
tion in the daily maintenance warfarin dose. Further studies to 
elucidate clinical utility of genotype-guided dosing and find 
additional genetic association are necessary. 
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